Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2022 | The need for disease-modifying drugs in myelofibrosis

Nicolaus Kröger • 28 Oct 2022
COSTEM 2022
Myelofibrosis Myeloproliferative Neoplasms

Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, describes current challenges in myelofibrosis management. The approval of various JAK inhibitors have improved outcomes in patients and research into BET inhibitors will add to the current armamentarium. However, there is a demand for disease-modifying compounds that can improve overall survival (OS). This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nicolaus Kröger

1:23
COSTEM 2023: congress highlights and importance
Nicolaus Kröger • 21 Oct 2023
0:35
The importance of bridging therapy in follicular and mantle cell lymphoma
Nicolaus Kröger • 28 Oct 2022
1:31
CAR-T therapy versus autoSCT in DLBCL
Nicolaus Kröger • 28 Oct 2022
1:36
The role of molecular markers in patient selection for transplantation in myelofibrosis
Nicolaus Kröger • 28 Oct 2022

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals